Arsenite activates NFκB through induction of C-reactive protein

Toxicology and Applied Pharmacology

Volumn 261, Issue 3, 2012, Pages 263-270

  Druwe, Ingrid L ^a   Sollome, James J ^a   Sanchez Soria, Pablo ^a   Hardwick, Rhiannon N ^a   Camenisch, Todd D ^a   Vaillancourt, Richard R ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Arsenite; CRP; Metabolic syndrome

Indexed keywords

ARSENIC TRIOXIDE; C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; RHO KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; ENVIRONMENTAL EXPOSURE; FEMALE; KIDNEY CELL; LIVER CELL; METABOLIC DISORDER; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION;

AMIDES; ANIMALS; ARSENITES; BIOLOGICAL MARKERS; BIOTRANSFORMATION; BLOTTING, WESTERN; C-REACTIVE PROTEIN; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; L-LACTATE DEHYDROGENASE; LIVER; LUCIFERASES; MICE; NF-KAPPA B; PROTEIN KINASE INHIBITORS; PYRIDINES; REACTIVE OXYGEN SPECIES; RHO-ASSOCIATED KINASES; TRANSFECTION;

MUS;

EID: 84861235577     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.04.005     Document Type: Article

References (54)

1. Achanzar W.E., Brambila E.M., et al. Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J Natl Cancer Inst. 2002, 94(24):1888-1891.
2. Ahmed S., Mahabbat-e Khoda S., et al. Arsenic-associated oxidative stress, inflammation, and immune disruption in human placenta and cord blood. Environ. Health Perspect. 2011, 119(2):258-264.
3. Baeuerle P.A., Baltimore D. NF-kappa B: ten years after. Cell 1996, 87(1):13-20.
4. Baeuerle P.A., Henkel T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 1994, 12:141-179.
5. Banerjee N., Nandy S., et al. Polymorphisms in the TNF-alpha and IL10 gene promoters and risk of arsenic-induced skin lesions and other nondermatological health effects. Toxicol. Sci. 2011, 121(1):132-139.
6. Barchowsky A., Dudek E.J., et al. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic. Biol. Med. 1996, 21(6):783-790.
7. Berg P., Lindelof B. Differences in malignant melanoma between children and adolescents. A 35-year epidemiological study. Arch. Dermatol. 1997, 133(3):295-297.
8. Binder B.R., Christ G., et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol. Sci. 2002, 17:56-61.
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
10. Bredfeldt T.G., Jagadish B., et al. Monomethylarsonous acid induces transformation of human bladder cells. Toxicol. Appl. Pharmacol. 2006, 216(1):69-79.
11. Calo L.A., Pagnin E., et al. Rho/Rho-kinase and C-reactive protein relationship in hypertension and atherosclerosis. Nephrol. Dial. Transplant. 2006, 21(4):1131-1132.
12. Chappell W.R., Abernathy C.O., et al. Arsenic Exposure and Health Effects: Proceedings of the Third International Conference on Arsenic Exposure and Health Effects, July 12-15, 1998, San Diego, California 1999, Chapman & Hall, Amsterdam; New York. 1st edn.
13. Chen C.J., Kuo T.L., et al. Arsenic and cancers. Lancet 1988, 1(8582):414-415.
14. Chen C.J., Chiou H.Y., et al. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler. Thromb. Vasc. Biol. 1996, 16(4):504-510.
15. Coronado-Gonzalez J.A., Del Razo L.M., et al. Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ. Res. 2007, 104(3):383-389.
16. D'Alessandris C., Lauro R., et al. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia 2007, 50(4):840-849.
17. Depraetere S., Willems J., et al. Stimulation of CRP secretion in HepG2 cells: cooperative effect of dexamethasone and interleukin 6. Agents Actions 1991, 34(3-4):369-375.
18. Dong M., Yan B.P., et al. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov. Today 2010, 15(15-16):622-629.
19. Druwe I.L., Vaillancourt R.R. Influence of arsenate and arsenite on signal transduction pathways: an update. Arch. Toxicol. 2010, 84(8):585-596.
20. Escudero-Lourdes C., Medeiros M.K., et al. Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model. Toxicol. Appl. Pharmacol. 2010, 244(2):162-173.
21. Fauci A.S. Harrison's Principles of Internal Medicine 2008, McGraw-Hill Medical, New York. 17th edn. A.S. Fauci (Ed.).
22. Festa A., D'Agostino R., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102(1):42-47.
23. Festa A., D'Agostino R., et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51(4):1131-1137.
24. Ford E.S. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999, 22(12):1971-1977.
25. Fry R.C., Navasumrit P., et al. Activation of inflammation/NF-kappaB signaling in infants born to arsenic-exposed mothers. PLoS Genet. 2007, 3(11):e207.
26. Ghosh J., Das J., et al. Taurine prevents arsenic-induced cardiac oxidative stress and apoptotic damage: role of NF-kappa B, p38 and JNK MAPK pathway. Toxicol. Appl. Pharmacol. 2009, 240(1):73-87.
27. Ishizaki T., Uehata M., et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 2000, 57(5):976-983.
28. Kvan E., Pettersen K.I., et al. High mortality in diabetic patients with acute myocardial infarction: cardiovascular co-morbidities contribute most to the high risk. Int. J. Cardiol. 2007, 121(2):184-188.
29. Lai M.S., Hsueh Y.M., et al. Ingested inorganic arsenic and prevalence of diabetes mellitus. Am. J. Epidemiol. 1994, 139(5):484-492.
30. Lara-Castro C., Fu Y., et al. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr. Opin. Lipidol. 2007, 18(3):263-270.
31. Lemaire M., Lemarie C.A., et al. Exposure to moderate arsenic concentrations increases atherosclerosis in ApoE-/- mouse model. Toxicol. Sci. 2011, 122(1):211-221.
32. Liu J., Kadiiska M.B., et al. Stress-related gene expression in mice treated with inorganic arsenicals. Toxicol. Sci. 2001, 61(2):314-320.
33. Martinez-Finley E.J., Ali A.M., et al. Learning deficits in C57BL/6J mice following perinatal arsenic exposure: consequence of lower corticosterone receptor levels?. Pharmacol. Biochem. Behav. 2009, 94(2):271-277.
34. Montaner S., Perona R., et al. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J. Biol. Chem. 1998, 273(21):12779-12785.
35. Navas-Acien A., Silbergeld E.K., et al. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 2008, 300(7):814-822.
36. Navas-Acien A., Silbergeld E.K., et al. Rejoinder: Arsenic exposure and prevalence of type 2 diabetes: updated findings from the National Health Nutrition and Examination Survey, 2003-2006. Epidemiology 2009, 20(6):816-820. discussion e811-812.
37. Norhammar A., Malmberg K., et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J. Am. Coll. Cardiol. 2004, 43(4):585-591.
38. Nossaman B.D., Nossaman V.E., et al. Role of the RhoA/Rho-kinase pathway in the regulation of pulmonary vasoconstrictor function. Can. J. Physiol. Pharmacol. 2010, 88(1):1-8.
39. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J. Clin. Invest. 2003, 111(12):1805-1812.
40. Pepys M.B., Hirschfield G.M., et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006, 440(7088):1217-1221.
41. Pradhan A.D., Manson J.E., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286(3):327-334.
42. Sanchez-Soria P., Broka D., Monks S.L., Camenisch T.D. Chronic low-level arsenite exposure through drinking water increases blood pressure and promotes left ventricular hypertrophy. Toxicol. Pathol. 2012, 40(3). (Electronic publication ahead of print, 2012 Jan 3).
43. Schwedler S.B., Guderian F., et al. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol. Dial. Transplant. 2003, 18(11):2300-2307.
44. States J.C., Srivastava S., et al. Arsenic and cardiovascular disease. Toxicol. Sci. 2009, 107(2):312-323.
45. Sturlan S., Baumgartner M., et al. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 2003, 101(12):4990-4997.
46. Suzuki S., Arnold L.L., et al. Effects of co-administration of dietary sodium arsenite and an NADPH oxidase inhibitor on the rat bladder epithelium. Toxicology 2009, 261(1-2):41-46.
47. Temelkova-Kurktschiev T., Henkel E., et al. Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. Diabetologia 2002, 45(1):151.
48. Thompson D., Pepys M.B., et al. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999, 7(2):169-177.
49. Travers P., Janeway C.A., et al. Immunobiology: The Immune System in Health and Disease 2001, Garland Publishing, New York, N.Y. 5. edn.
50. Tseng C.H., Tai T.Y., et al. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ. Health Perspect. 2000, 108(9):847-851.
51. Wang C.H., Jeng J.S., et al. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 2002, 105(15):1804-1809.
52. Wu M.M., Chiou H.Y., et al. Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ. Health Perspect. 2003, 111(11):1429-1438.
53. Xue P., Hou Y., et al. Prolonged inorganic arsenite exposure suppresses insulin-stimulated AKT S473 phosphorylation and glucose uptake in 3T3-L1 adipocytes: involvement of the adaptive antioxidant response. Biochem. Biophys. Res. Commun. 2011, 407(2):360-365.
54. Zhu X.H., Shen Y.L., et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl Cancer Inst. 1999, 91(9):772-778.